A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Sponsor
Hanmi Pharmaceutical Company Limited
Study ID
NCT07660796
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • HCP1803-3 — DRUG
    Test drug
  • HCP1803-4 — DRUG
    Test drug
  • RLD2001-1 — DRUG
    Control drug
  • RLD2001-2 — DRUG
    Control drug

Study Details

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Key Dates

First listed
Jun 22, 2026
Start date
Jul 6, 2026
Status verified
Jun 2026
Primary completion
Oct 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
256 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HCP1803-4
    Take HCP1803-3 once daily for 2 weeks orally, and then take HCP1803-4 once daily for 8 weeks orally.
  • Active Comparator: RLD2001-2
    Take RLD2001-1 once daily for 2 weeks orally, and then take RLD2001-2 once daily for 8 weeks orally.

Primary Outcome Measure

Change from baseline in sitting systolic blood pressure [ Time Frame: Baseline, 10 weeks ]

Central Contacts

Find similar trials

Nationwide
Hypertension (high blood pressure) trialsCardiology trialsHeart disease trials

Related Studies